What is OncoQuest?
OncoQuest functions as a private biopharmaceutical entity dedicated to the rigorous development and commercialization of novel immunotherapies designed to combat various forms of cancer. By leveraging a sophisticated technology platform, the company maintains a robust portfolio of tumor antigen-specific monoclonal immunoglobulins, including targets such as CA-125, MUC1, PSA, and Her2/neu. The organization distinguishes itself by exploring the therapeutic synergy between these antibodies and other immune-modulating agents, aiming to significantly enhance tumor-specific immunity and improve long-term clinical outcomes for patients. As a subsidiary of Quest PharmaTech Inc., OncoQuest benefits from a strategic alignment that facilitates the translation of complex biological research into viable clinical applications.
How much funding has OncoQuest raised?
OncoQuest has raised a total of $50M across 1 funding round:
Share Placement
$50M
Share Placement (2020): $50M with participation from Dual Industrial Co. Ltd.
Key Investors in OncoQuest
Dual Industrial Co. Ltd.
A diversified investment entity focused on supporting high-growth industrial and biopharmaceutical ventures through strategic capital allocation.
What's next for OncoQuest?
With the recent strategic investment, OncoQuest is positioned to accelerate its clinical development pipeline and expand its research capabilities. The focus will likely shift toward scaling the testing of its monoclonal antibody combinations, aiming to validate their efficacy in broader patient cohorts. By prioritizing the optimization of immune-modulating drug combinations, the company is set to strengthen its competitive standing within the global biopharmaceutical landscape. Future milestones will center on achieving key regulatory benchmarks and advancing its lead candidates through the critical phases of clinical trials, ultimately aiming to provide transformative solutions in the oncology sector.
See full OncoQuest company page
